Cellusion

Regenerative Medicine · Cell & Gene Therapy
No open roles listed
Data updated Nov 20, 2026Money ledger: 2 records from 2 sourcesAnnounced 2Full reportReport a mistake

Facts

as of Nov 20, 2026

Cellusion develops regenerative medicine therapies using induced pluripotent stem (iPS) cells focused on treating corneal endothelial diseases. The company is developing a proprietary minimally invasive cell therapy composed of corneal endothelial cells derived from iPS cells to reduce reliance on donor corneas and highly skilled surgeons. Its product targets patients with corneal blindness worldwide by enabling broader access to transplantation-like treatment options.

Employees
1001-5000estimated range

These are the key facts about Cellusion on Alion as of Nov 20, 2026. It has raised $2.8B in 2 funding rounds. The latest round is Series C of $2.8B, announced in 2023.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

Cellusion has $2.8B paid in by investors, lenders and donors.

$2.8BPaid in
Money innewest first
Equity raised
Jun 2023 · Series C
$2.8BPaid
Equity raised
Jan 2022 · Venture round
$9.5MPaid
Money by yearUSD, rounds and grants
2023$2.8B1 record
2022$9.5M1 record
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".

Products

top 9%Web presenceof 133.2M domains by links, Common Crawl

Cellusion in public registers.

Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Patents
2
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Milestones
Jun 7, 2023
Raised a round Venture round $9.5M
Jan 17, 2022
Sources: the outlets named on each headline, each story once